---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-037968"
form_type: "8-K"
ticker: "SGHT"
cik: "0001531177"
company_name: "Sight Sciences, Inc."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:07:39.012882+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sight Sciences Q2 revenue $23.5M (+36% YoY); net loss narrows to $14.8M; reaffirms FY guidance

## Summary
- Revenue $23.5M, +36% YoY; Surgical Glaucoma $21.4M (+35%), Dry Eye $2.1M (+56%).
- Net loss $14.8M ($0.30/share) vs $23.8M ($0.50) prior year; operating expenses down 6%.
- Gross margin 85.6% (vs 84.1% prior year); cash $154.5M; long-term debt $35.0M.
- FY2023 revenue guidance reaffirmed at $89-94M (25-32% YoY growth); quarterly adjusted opex ~$30.5M.
- SAHARA trial met primary signs endpoint at 6 months; Cigna covers OMNI procedures (15M lives).

## SEC filing metadata
- accession: 0000950170-23-037968
- form_type: 8-K
- ticker: SGHT
- cik: 0001531177
- company_name: Sight Sciences, Inc.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/0000950170-23-037968-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/sght-20230803.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-037968
- JSON: https://secwatch.observer/filing/0000950170-23-037968.json
- Plain text: https://secwatch.observer/filing/0000950170-23-037968.txt

## Key facts
- Earnings Releases
  Sight Sciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $23.5 million. Guidance reaffirmed.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $23.5 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: second quarter ended June 30, 2023 and reaffirmed guidance for full year 2023. Recent Business and Financial Highlights • Generated record second quarter 2023 total revenue of $23.5 million, an increase of 36% compared to the prior year period • Achieved total gross margin of 85.6% in the second quarter of 2023 compared to 84.1% in the prior year period Dry Eye
  evidence_url: https://www.sec.gov/Archives/edgar/data/1531177/000095017023037968/0000950170-23-037968-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.